
Xingxing Diao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5694209/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites. Frontiers in Chemistry, 2019, 7, 109.	3.6	95
2	High-Resolution Mass Spectrometry for Characterizing the Metabolism of Synthetic Cannabinoid THJ-018 and Its 5-Fluoro Analog THJ-2201 after Incubation in Human Hepatocytes. Clinical Chemistry, 2016, 62, 157-169.	3.2	65
3	Metabolic profiling of new synthetic cannabinoids AMB and 5Fâ€AMB by human hepatocyte and liver microsome incubations and highâ€resolution mass spectrometry. Rapid Communications in Mass Spectrometry, 2016, 30, 1067-1078.	1.5	56
4	In Vitro and In Vivo Human Metabolism of Synthetic Cannabinoids FDU-PB-22 and FUB-PB-22. AAPS Journal, 2016, 18, 455-464.	4.4	50
5	Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry. Clinical Chemistry, 2017, 63, 1008-1021.	3.2	48
6	4-Methoxy-α-PVP: in silico prediction, metabolic stability, and metabolite identification by human hepatocyte incubation and high-resolution mass spectrometry. Forensic Toxicology, 2016, 34, 61-75.	2.4	46
7	<i>In vitro, in vivo</i> and <i>in silico</i> metabolic profiling of α-pyrrolidinopentiothiophenone, a novel thiophene stimulant. Bioanalysis, 2016, 8, 65-82.	1.5	44
8	25Câ€NBOMe and 25Iâ€NBOMe metabolite studies in human hepatocytes, <i>in vivo</i> mouse and human urine with highâ€resolution mass spectrometry. Drug Testing and Analysis, 2017, 9, 680-698.	2.6	43
9	In Vitro Metabolite Profiling of ADB-FUBINACA, A New Synthetic Cannabinoid. Current Neuropharmacology, 2017, 15, 682-691.	2.9	39
10	Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations. Journal of Medicinal Chemistry, 2022, 65, 3923-3942.	6.4	36
11	First metabolic profile of PV8, a novel synthetic cathinone, in human hepatocytes and urine by high-resolution mass spectrometry. Analytical and Bioanalytical Chemistry, 2016, 408, 4845-4856.	3.7	34
12	In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). Forensic Toxicology, 2017, 35, 20-32.	2.4	31
13	Identification of New Synthetic Cannabinoid ADB-CHMINACA (MAB-CHMINACA) Metabolites in Human Hepatocytes. AAPS Journal, 2017, 19, 568-577.	4.4	25
14	Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes. Forensic Toxicology, 2016, 34, 256-267.	2.4	21
15	Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection. Journal of Pharmaceutical and Biomedical Analysis, 2018, 157, 27-35.	2.8	21
16	Human Hepatocyte Metabolism of Novel Synthetic Cannabinoids MN-18 and Its 5-Fluoro Analog 5F-MN-18. Clinical Chemistry, 2017, 63, 1753-1763.	3.2	11
17	Metabolism of the new synthetic cannabinoid EC-018 in human hepatocytes by high-resolution mass spectrometry. Forensic Toxicology, 2018, 36, 304-312.	2.4	10
18	Metabolite identification of iridin in rats by using UHPLC-MS/MS and pharmacokinetic study of its metabolite irigenin. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1181, 122914.	2.3	9

#	Article	IF	CITATIONS
19	Pyrrolidinyl Synthetic Cathinones α-PHP and 4F-α-PVP Metabolite Profiling Using Human Hepatocyte Incubations. International Journal of Molecular Sciences, 2021, 22, 230.	4.1	9
20	In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry. Forensic Toxicology, 2017, 35, 252-262.	2.4	7